Genomic Vision SA

01/21/2020 | Press release | Distributed by Public on 01/21/2020 00:40

Genomic Vision Technology to Be Tested by NIST (US Gaithersburg) for Establishing Standards Methods for Genome Editing Based Product Registration by FDA

Genomic Vision Technology to Be Tested by NIST (US Gaithersburg) for Establishing Standards Methods for Genome Editing Based Product Registration by FDA

21 Jan 2020 07:30 CET

Company Name








Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 - GV), a biotechnology company developing molecular assays and Artificial Intelligence tools to control quality and safety of genetically modified genomes, today announced that its Molecular Combing technology will be used by the US National Institute of Standards and Technology (NIST) to characterize and quantify intended and unintended genome editing events in NIST's control material.

The Molecular Combing technology is currently used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision has been part of the NIST Genome Editing Consortium since March 2019. The consortium's goal is to address pre-competitive measurement needs which may eventually help to speed the process of bringing genome editing products to the market. The Consortium has 33 formal members and three working groups. Genomic Vision participates in the first working group, known as 'Specificity' which aims to qualify the genomic assays used for evaluating genome editing outputs, and to design the control materials needed to increase confidence in genome editing.

On October 18th, 2019, working group projects were defined and it was decided that Genomic Vision will use their Quality Control Assay (QCA) to confirm mid-size to large variants engineered into cells as controls. Indeed, Genomic Vision FiberVision® platform provides a powerful quality control tool for the safety and the optimization of gene editing projects thanks to its high sensitivity and digital quantification capacity. This platform allows an unbiased assessment of genetic events through the direct visualization on single DNA molecules. Combing technology requires no DNA amplification and completes NGS/PCR based assays.

Samantha Maragh, Leader of the Genome Editing Program at the NIST, stated: 'One of NIST's missions consists of playing a pivotal role in helping to define the measurements and standards for cellular and gene therapies and other regenerative medicine. I am glad to have innovative industry partners participating in the Consortium who can apply their technology to solving some of the measurement challenges of genome editing.'

The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories, and addresses measurement research needs in multiple fields including chemistry, IT, engineering and biology. The NIST Genome Editing Consortium addresses the measurements and standards needed to increase confidence and lower the risk of utilizing genome editing technologies in research and commercial products (

Stéphane Altaba, Chief Operating Officer of Genomic Vision, commented: 'Implementing our technology in the scope of the NIST consortium into specific work packages will confirm the value of the molecular combing in detecting and quantifying unwanted events. The work we have performed in collaboration with Editas Medicine (Cecilia Cotta-Ramusino et al., CSHL Meeting: Genome Engineering: The CRISPR-Cas9 Revolution, July 21-23, 2017) and for other gene editing companies already demonstrated the relevance of our technology in this field but we wanted to take the time to go along the regulatory pathway and join the NIST Consortium. We appreciate the way that this initiative will enable us to interact on a regular basis with all the major players in gene editing and will give us the opportunity to use our technology to set up standard tools. It is exciting to contribute to the fabulous story of gene editing.'

GENOMIC VISION is a biotechnology company developing molecular assays and Artificial Intelligence tools to control quality and safety of genetically modified genomes, in particular in genome editing technologies and biomanufacturing processes. These tools are currently used for monitoring DNA replication in cancerous cells, for early cancer detection, and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a publicly listed company in compartment C of Euronext's regulated market in Paris (Euronext: GV - ISIN: FR0011799907).

For further information, please visit

Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 'Risk Factors' section of the reference document dated March 28, 2017, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

View source version on

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
+33 1 49 08 07 50
[email protected]

Ulysse Communication
Bruno Arabian
+33 1 42 68 29 70
[email protected]

Investor Relations / Strategic Communications
+33 1 44 71 94 92
[email protected]